BR112019010485A2 - método para a produção de um anticorpo, anticorpo e formulação farmacêutica - Google Patents

método para a produção de um anticorpo, anticorpo e formulação farmacêutica

Info

Publication number
BR112019010485A2
BR112019010485A2 BR112019010485A BR112019010485A BR112019010485A2 BR 112019010485 A2 BR112019010485 A2 BR 112019010485A2 BR 112019010485 A BR112019010485 A BR 112019010485A BR 112019010485 A BR112019010485 A BR 112019010485A BR 112019010485 A2 BR112019010485 A2 BR 112019010485A2
Authority
BR
Brazil
Prior art keywords
antibody
producing
pharmaceutical formulation
affinity ligand
chain affinity
Prior art date
Application number
BR112019010485A
Other languages
English (en)
Inventor
Walch Heiko
Grunert Ingrid
Thomann Marco
Freiherr Von Roman Matthias
Hingar Michael
Falkenstein Roberto
Dorn Roland
Malik Sebastian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60997429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019010485(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112019010485A2 publication Critical patent/BR112019010485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

a presente invenção se refere a um método para a produção de um anticorpo que compreende as etapas para formar um complexo de ligante de afinidade de cadeia leve anticorpo-anticorpo, em que o ligante de afinidade de cadeia leve de anticorpo é imobilizado em uma fase sólida, através da aplicação de uma solução que compreende o anticorpo para o ligante de afinidade de cadeia de anticorpo imobilizado, e incubação do complexo formado na etapa anterior com uma ou mais enzimas para modificar a glicosilação do anticorpo, por conseguinte, produzindo o anticorpo.
BR112019010485A 2016-12-21 2017-12-19 método para a produção de um anticorpo, anticorpo e formulação farmacêutica BR112019010485A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16205587 2016-12-21
EP17157002 2017-02-20
PCT/EP2017/083429 WO2018114877A1 (en) 2016-12-21 2017-12-19 In vitro glycoengineering of antibodies

Publications (1)

Publication Number Publication Date
BR112019010485A2 true BR112019010485A2 (pt) 2019-09-10

Family

ID=60997429

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019010485A BR112019010485A2 (pt) 2016-12-21 2017-12-19 método para a produção de um anticorpo, anticorpo e formulação farmacêutica

Country Status (12)

Country Link
US (2) US20200165320A1 (pt)
EP (1) EP3559248B1 (pt)
JP (1) JP6850351B2 (pt)
KR (1) KR102317884B1 (pt)
CN (1) CN110088291A (pt)
AU (1) AU2017384276B9 (pt)
BR (1) BR112019010485A2 (pt)
CA (1) CA3044920C (pt)
IL (1) IL267351A (pt)
MX (1) MX2019006266A (pt)
TW (1) TWI780097B (pt)
WO (1) WO2018114877A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019006266A (es) 2016-12-21 2019-08-21 Hoffmann La Roche Glucomanipulacion in vitro de anticuerpos.
IL267352B2 (en) * 2016-12-21 2023-10-01 Hoffmann La Roche A method for in vitro glycoengineering of antibodies
JP2021526845A (ja) 2018-07-13 2021-10-11 ゲンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
SG11202012993SA (en) 2018-07-13 2021-02-25 Genmab As Variants of cd38 antibody and uses thereof
WO2021144457A1 (en) 2020-01-16 2021-07-22 Genmab A/S Formulations of cd38 antibodies and uses thereof
US20230109496A1 (en) 2021-09-06 2023-04-06 Genmab B.V. Antibodies capable of binding to cd27, variants thereof and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE193551T1 (de) 1991-03-18 2000-06-15 Scripps Research Inst Oligosaccharide als enzymsubstrate und - inhibitoren: verfahren und zusammensetzungen
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1460425A1 (en) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Deglycosylated enzymes for conjugates
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20070266448A1 (en) 2006-05-11 2007-11-15 Alexander Lifke Method for the production of antibodies
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CN101784670A (zh) * 2007-08-31 2010-07-21 弗·哈夫曼-拉罗切有限公司 糖基化谱分析
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
ES2538819T3 (es) 2009-07-30 2015-06-24 F. Hoffmann-La Roche Ag Procesamiento enzimático de anticuerpos
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20130171658A1 (en) 2010-09-17 2013-07-04 Prozyme, Inc. Isolation and deglycosylation of glycoproteins
EP2768857B1 (en) * 2011-10-19 2020-01-01 NovImmune SA Methods of purifying antibodies
US9434786B2 (en) * 2012-02-10 2016-09-06 University Of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
WO2015123754A1 (en) * 2014-02-18 2015-08-27 The University Of Manitoba Methods to produce single glycoform antibodies
JP2017528468A (ja) * 2014-09-10 2017-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ガラクトース操作型免疫グロブリン１抗体
MX2019006266A (es) 2016-12-21 2019-08-21 Hoffmann La Roche Glucomanipulacion in vitro de anticuerpos.

Also Published As

Publication number Publication date
KR20190082942A (ko) 2019-07-10
CA3044920C (en) 2022-06-28
US20200165320A1 (en) 2020-05-28
JP6850351B2 (ja) 2021-03-31
AU2017384276A1 (en) 2019-05-30
IL267351A (en) 2019-08-29
AU2017384276B2 (en) 2020-07-02
EP3559248B1 (en) 2021-11-17
KR102317884B1 (ko) 2021-10-26
EP3559248A1 (en) 2019-10-30
CN110088291A (zh) 2019-08-02
CA3044920A1 (en) 2018-06-28
US20240101643A1 (en) 2024-03-28
MX2019006266A (es) 2019-08-21
AU2017384276B9 (en) 2020-11-26
TW201835333A (zh) 2018-10-01
TWI780097B (zh) 2022-10-11
WO2018114877A1 (en) 2018-06-28
JP2020501577A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
BR112019010485A2 (pt) método para a produção de um anticorpo, anticorpo e formulação farmacêutica
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112015017606A2 (pt) composição, método de produzir a composição, utilização da composição e combustível obtido a partir da composição
BR112019000718A2 (pt) processo para a produção de geopolímero ou compósito de geopolímero
BR112016015496A2 (pt) composição e processo para a produção da composição
BR112012023276A2 (pt) dispositivo e método de processamento de imagem, e , dispositivo de armazenamento não transitório legível por computador
BR112019005328A2 (pt) composição farmacêutica líquida
BR112015032445A2 (pt) componente semicondutor orgânico
BR112017018028A2 (pt) método de produção de compostos lignocelulósicos
BR112019009839A2 (pt) método para a produção enzimática de um anticorpo e anticorpo
BR112017023238A2 (pt) artigo e método de formação de um artigo
BR112016001730A2 (pt) Processo para a preparação de um componente neurotóxico altamente puro de uma toxina botulínica, componente neurotóxico altamente puro de uma toxina de clostridium botulinum e composição farmacêutica
BR112018002036A2 (pt) método para o controle das pragas de um vegetal de algodão e utilização de um ou mais componentes da árvore de ginkgo
BR112018069741A2 (pt) composição para aplicação tópica, e, método para fabricar uma composição para aplicação tópica.
BR112017010453A2 (pt) composição adesiva com mudança de cor
BR112013020873A2 (pt) endoprótese e método para revestimento de uma endoprótese
BR112018070130A2 (pt) método para a coloração parcial de peças plásticas
BR112017008961A2 (pt) precursor de recipiente, processo, recipiente fechado e uso do precursor de recipiente
AR107327A1 (es) Productos alimenticios revestidos
BR112017016578A2 (pt) controle do pré-tratamento de um material de partida de madeira macia
BR112019010294A2 (pt) método para a produção enzimática de um anticorpo, anticorpo e formulação farmacêutica
BR102014004766A8 (pt) conjunto de freio com uma asa de freio
BR112017011314A2 (pt) microcápsula, processo para produzir microcápsulas, dispersão aquosa, e, uso de uma microcápsula.
BR112016029309A2 (pt) reconhecimento de padrão com um estêncil não detectável na superfície sensível ao toque
BR112017009162A2 (pt) métodos para aperfeiçoamento de planta

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]